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Abstract
Background: Animal models are frequently used to assess new treatment methods in cancer research. MRI offers
a non-invasive in vivo monitoring of tumour tissue and thus allows longitudinal measurements of treatment effects,
without the need for large cohorts of animals. Tumour size is an important biomarker of the disease development,
but to our knowledge, MRI based size measurements have not yet been verified for small tumours (10−2–10−1 g).
The aim of this study was to assess the accuracy of MRI based tumour size measurements of small tumours on
mice.
Methods: 2D and 3D T2-weighted RARE images of tumour bearing mice were acquired in vivo using a 7 T
dedicated animal MR system. For the 3D images the acquired image resolution was varied. The images were
exported to a PC workstation where the tumour mass was determined assuming a density of 1 g/cm3, using an
in-house developed tool for segmentation and delineation. The resulting data were compared to the weight of
the resected tumours after sacrifice of the animal using regression analysis.
Results: Strong correlations were demonstrated between MRI- and necropsy determined masses. In general,
3D acquisition was not a prerequisite for high accuracy. However, it was slightly more accurate than 2D when small
(<0.2 g) tumours were assessed for inter- and intraobserver variation. In 3D images, the voxel sizes could be
increased from 1603 μm3 to 2403 μm3 without affecting the results significantly, thus reducing acquisition time
substantially.
Conclusions: 2D MRI was sufficient for accurate tumour size measurement, except for small tumours (<0.2 g)
where 3D acquisition was necessary to reduce interobserver variation. Acquisition times between 15 and 50
minutes, depending on tumour size, were sufficient for accurate tumour volume measurement. Hence, it is
possible to include further MR investigations of the tumour, such as tissue perfusion, diffusion or metabolic
composition in the same MR session.
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Background
The efficacy of new tumour treatment methods are usu-
ally tested in animal models prior to clinical trials
(e.g. [1-3]). The end-point studied is often the change in
tumour size using mice with subcutaneous xenografts of
human tumour tissue (e.g. [4]). Two or three perpen-
dicular diameters of the tumour are measured and vol-
ume is calculated under assumptions of e.g. ellipsoidal
tumour shape (e.g. [5]). These methods are fast,
inexpensive, and do not require anaesthesia. Studies on
orthotopic and metastatic tumour models have increased
[6-9]. Generally, such studies exclude external volume
measurements and require non-invasive imaging techni-
ques, such as magnetic resonance imaging (MRI), com-
puted tomography (CT), positron emission tomography
or single photon emission computed tomography
[10, 11].
MicroCT imaging allows accurate measurement of
very small tumour volumes (~10−2 g) in short acquisi-
tion time [12], but the radiation exposure might affect
tumour growth and thus confound the interpretation of
the treatment results. MRI does not expose the animal
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to ionizing radiation and gives no known side effects
which opens the possibility to follow the same animal by
consecutive non-invasive measurements in longitudinal
studies. In addition, MRI has intrinsic contrast abilities
which can be used to assess tumour tissue characteris-
tics, e.g. diffusion, perfusion and metabolic properties,
parameters reflecting cell proliferation, apoptosis, vascu-
larisation, etc. [11, 13-21].
Multiparametric MR imaging requires optimised MR
methods for minimum time consumption. Small
tumours require careful attention regarding imaging
parameters due to the partial volume effect (PVE). To
our knowledge, there is a lack of information on the ac-
curacy and precision of MRI based size measurements
on small tumours.
The aim of this study was 1) to develop and assess the
accuracy of an MRI based method for in vivo measure-
ment of tumour size in a small animal tumour model,
and 2) to investigate the possibility to reduce acquisition
time by reducing image resolution, without affecting the
accuracy.
Methods
Tumour models and experimental setup
The study was performed on 17 tumour bearing female,
athymic BALB/c and SCID mice s.c. inoculated in the
neck/back region with the human midgut carcinoid cell
line, GOT1 (n = 15), or the medullary thyroid carcinoma,
GOT2 (n = 2) under anaesthesia using tribromoethanol
(AvertinW, Winthrop Laboratories, Surbiton, UK). Ani-
mals had free access to water and standard diet.
Within two days after MR imaging, animals were
sacrificed by surgical incision of the heart after i.p. injec-
tion of sodium pentobarbital (Apoteket Farmaci, Stock-
holm, Sweden). Gauge block measurements of the
length, l, width, w and height, h of the tumours were
performed. Assuming ellipsoidal tumours, the volume
V= (π/6)lwh, was determined and converted to mass,
mGB, assuming a tumour density of 1.0 g/cm
3. The
tumour was then surgically removed and weighed for
reference tumour mass, mT, determination. All proce-
dures were approved by the local Animal ethics commit-
tee in Gothenburg.
MR imaging
MRI was performed using a 7 T MR system (Bruker
BioSpin MRI GmbH, Ettlingen, Germany; software:
ParaVision 5.0) equipped with water cooled gradient
coils (maximum gradient strength 400 mT/m). A 72 mm
volume coil was used for transmission and an actively
decoupled 4 channel array rat brain coil was used for
signal receiving (RAPID Biomedical GmbH, Rimpar,
Germany). Proper animal positioning was assured using
a fast gradient-echo localizer scan. All other imaging
experiments were based on a respiration triggered and
fat suppressed T2-weighted rapid acquisition with relax-
ation enhancement (RARE) sequence [22]. A 2D set of
axial images was acquired (TR= 3438–4186 ms,
TEeff = 30 ms, NSA= 2–5, turbo factor Tf = 4, pixel size:
~150200 μm2, slice thickness = 700 μm) prior to a 3D
volume acquisition (TR= 3000 ms, TEeff = 35–82 ms,
NSA= 1–2, Tf = 4–14). In the 3D acquisition, the matrix
size was adjusted to achieve 1603 μm3 voxels with min-
imal field-of-view (FOV) but full tumour coverage. The
3D sequence was repeated twice using voxel sizes of
2003 μm3 and 2403 μm3 but with maintained FOV. The
methods are henceforth designated 3D-160, 3D-200 and
3D-240, respectively. Saturation slices were always used
in the phase encoding direction.
During the MRI experiments anaesthesia was main-
tained using a mixture of air and isoflurane (1.5–2.0 %)
(Isoba vet., Schering-Plough Animal-health, Farum,
Denmark). Body temperature was maintained with a heat-
ing pad on the animal bed and a pressure sensitive pad was
used for respiratory triggering.
Image processing and tumour mass estimation
The image series were processed on a PC workstation
using an in house developed volume estimation tool
implemented in MATLAB (R2008b, The MathWorks,
USA). Figure 1 shows the volume determination process.
The average signal from a manually outlined region con-
taining approximately equal amounts of tumour and
background tissue was used for threshold segmentation
(Figure 1b). Successful segmentation was ensured by
allowing threshold adjustment on an image by image
basis, and a polygon function could be used to manually
exclude regions where the segmentation had failed
(Figure 1b, c). With the tumour border properly defined,
regions of low intra-tumour signal intensity, erroneously
assigned to the background compartment, were con-
verted using a growing seed algorithm, and the resulting
image was used for volume calculation (Figure 1b, d).
The number of tumour voxels, multiplied by the voxel
volume, was converted to mass assuming a tumour
density of 1.0 g/cm3. The estimated masses from the 2D
and 3D images, denoted m2D and m3D respectively, were
compared to mT using regression analysis.
The operator determining the masses from the
repeated scans with increasing voxel sizes (m3D-160, m3D-
200, and m3D-240) was blinded to images with higher
resolution when such existed.
Intra- and interobserver variability
Repeated (n = 10) segmentation and mass calculation was
performed to investigate the intraobserver variability.
Five image series including a small tumour (mT= 0.01,
2D and 3D-160), a medium sized tumour (mT= 0.10 g,
Montelius et al. BMC Medical Imaging 2012, 12:12 Page 2 of 7
http://www.biomedcentral.com/1471-2342/12/12
3D-160) and a large tumour (mT=0.87 g, 2D and 3D-160)
were included in the assessment. The operator was
blinded to the 3D images when evaluating the 2D images.
Learning effects were minimized by presenting the image
series in a random order and allowing at least several
hours to pass between sessions. The coefficient of vari-
ation (CV) was calculated for each image series.
Two additional observers repeated the process on the
five image series to investigate interobserver variations.
Their results were compared to the corresponding aver-
age values obtained by observer 1 in the intraobserver
assessment.
Estimation of influence of partial volume effect
A simulation was set up using MATLAB to quantify the
maximum influence that PVE could have on volume
estimations based on 3D MRI images of a spherically
shaped tumour. Tumour diameter and voxel dimensions
were used as input parameters. A 3D grid was used to
simulate the image matrix, with grid elements acting as
image voxels. A sphere, simulating the tumour, was
superimposed on the grid with coinciding origins. Grid
elements located inside and outside the sphere were
defined as tumour and background elements, respect-
ively. Elements intersected by the rim of the sphere were
defined as PVE elements. Each one-element thick sec-
tion of the grid (representing the image slices) was con-
sidered for two extreme cases of segmentation, where
PVE elements were classified either as tumour elements,
or as background elements, thus overestimating or
underestimating the true tumour volume, respectively.
The total influence of PVE on the tumour volume esti-
mation was defined as ~VVV  100 %, where ~V represents the
total volume of tumour elements in the simulation and V is
the true tumour volume. Voxel sizes of 1003–2503 μm3 and
3–9 mm (diameter) tumours were simulated, and the
resulting data were presented as relative volume errors
for different number of voxels-per-tumour-diameter
ratios.
Statistics
Regression analyses were performed using the Microsoft
Excel (2003) statistics toolkit. Pearson’s r squared correl-
ation coefficient was used.
Results
Determination of tumour mass
All tumours found at necropsy were well visualized in
the MR images. The mass of the resected tumours, mT,
was between 0.01 g and 2.28 g. Tumours with mT <0.2 g
are henceforth classified as small.
A strong correlation was found between the tumour
mass estimated from the 3D-160 MR images (m3D-160)
and mT (Figure 2). The correlation was persistent when
data only from the small tumours (mT < 0.2 g) were
included.
Figure 2 Tumour mass calculated from 3D-160 MR images,
m3D-160, vs. tumour mass measured after resection, mT, n = 17.
There is a strong correlation between the parameters. The inserted
figure shows the same data when only small tumours (<0.2 g) are
included (m3D-160= 0.90mT+ 0.00, R
2 = 0.98, n = 10).
Figure 1 a) 3D-160 MR image of a subcutaneous GOT1 tumour positioned in the neck of the mouse. The tumour is visible as the
hyper-intense region central to the image, marked by the 1 cm vertical bar. b) The global segmentation threshold is applied and regions of
failed segmentation appear outside the tumour. c) The manual delineation excludes the areas of failed segmentation, and the final result is
shown in d) where white pixels represent the region that will be accounted for as tumour volume.
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In twelve mice, tumours were measured with gauge
blocks in addition to MRI and digital balance. The cor-
relation between mGB and mT was strong when data
from all tumours were included (Figure 3a). When ana-
lysing small tumours only, the correlation was markedly
reduced (R2 = 0.65). The same subset of tumours ana-
lysed with the 3D-160 method yielded R2 = 0.97.
Comparing m2D to mT (n = 15, one image series was
lost, and one did not cover the entire tumour) a strong
correlation was obtained (R2 = 0.99) (Figure 3b). Also for
small tumours a strong correlation was found (R2 = 0.96),
i.e. the 2D method was comparable to the 3D-160 method
regarding accuracy.
To exclude the inherent uncertainty of the digital
balance, m2D was compared directly to m3D-160. The lin-
ear relation in the regression and the correlation
approached unity m2D= 1.01m3D-160–0.00, R
2 = 1.00,
n = 15. For small tumours the corresponding relation
was m2D =1.04 m3D-160+ 0.00, R
2 = 0.99, n = 9.
The analysis of m3D-160, m3D-200, and m3D-240 vs. mT
did not reveal any obvious voxel size dependence in the
range of tumour- and voxel sizes investigated. The ac-
quisition time required for the smallest tumour studied
(mT= 0.01 g) was clearly reduced with larger voxels: 55,
34 and 22 minutes for the 1603, 2003 and 2403 μm3
images, respectively.
Intra- and interobserver variability
The intraobserver variation was in general low for each
method and tumour size (CV of 2–3 %), but an indica-
tion of increased variability (CV of 7 %) was observed in
the 2D image set of the smallest tumour (Table 1).
The interobserver results indicated a difference be-
tween the 2D and 3D-160 methods (Table 2). The rela-
tive deviation from the average mass was higher when
determined from the 2D images compared to the 3D-160
images. The effect was more pronounced for the smallest
tumour size.
Computer simulation
Table 3 shows data from the simulations of the max-
imum possible influence that PVE could have on volume
estimation. The largest relative volume error was ap-
proximately 40 % for a voxels-per-tumour-diameter ratio
of 12, corresponding to, e.g., a tumour of 3 mm diameter
(~0.01 g) imaged with the voxel size set to 2503 μm3, i.e.
the smallest tumour included in this study, in combin-
ation with the largest voxel size used in the imaging
experiments.
Discussion
The present study evaluated the possibilities and require-
ments for accurate measurement of small tumour sizes
Figure 3 Tumour mass calculated from a) gauge block measurements, mGB, and b) 2D images, m2D, vs. tumour mass measured after
resection, mT. a) mGB vs. mT (n = 12). The correlation was strong when all tumour sizes were included (R
2 = 1.0), but was lower in the assessment
of small tumours only (inserted figure; mT <0.2 g, n = 9, mGB= 0.78mT+ 0.00, R
2 = 0.65). The corresponding correlation for m3D-160 vs. mT for the
same set of tumours was m3D-160= 0.93mT+ 0.00, R
2 = 1.00 (mT <0.2 g: m3D-160= 0.90mT+ 0.00, R
2 = 0.97). b) m2D vs. mT (n = 15).
The correlation was strong when all tumour sizes were included (R2 = 0.99), and persisted in the assessment of small tumours only (inserted
figure, mT <0.2 g, n = 9, m2D= 0.94mT+ 0.00, R
2 = 0.96). The corresponding correlation for m3D-160 vs. mT for the same set of tumours
was m3D-160= 0.93mT+ 0.01, R
2 = 1.0 (<0.2 g: m3D-160= 0.91mT+ 0.00, R
2 = 0.98).
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in mice using MRI. A linear, highly correlated relation-
ship between weighed and MRI measured tumour
masses down to 10−2 g was found. 3D acquisition should
be considered when tumour masses of 10−1 gram or less
are expected, due to the relative increase of PVE. In very
small tumours (10−2 g) image acquisition at high reso-
lution (in our setup 1603 μm3 voxels) should also be con-
sidered. The increased acquisition time using high
resolution is compensated for by the smaller FOV needed
to cover the tumour. Short acquisition times allow either
additional MR investigations on the same animal, such as
determining tumour diffusion, perfusion or metabolic
parameters within one MR session, or a higher animal
throughput.
Initially, the 2D method was included only for anatom-
ical reference since gradient performance limited the
minimum slice thickness to 700 μm, resulting in sub-
stantial PVE. However, the accuracy of volume estima-
tions based on the 2D images was similar to that based
on the 3D images (Figures 2 and 3b). This might be due
to the possibility to study adjacent image slices, which
probably improves the view of the tumour shape and de-
lineation of the tumour border. However, the 2D method
has a higher interobserver variability (Table 2), which
supports the use of a 3D method for very small tumours,
in order to limit the subjectivity in the evaluation.
In the 3D method, the turbo factor (Tf) was adjusted to
reduce acquisition time. An increase in Tf results in an
increased point spread function (PSF). Computer simula-
tions assuming similar acquisition parameters as those
used, and T2 values common at 7 T [23] showed that the
PSF was broadened only by a factor of 1.6 compared to the
value for Tf= 1 (data not shown). The minimum TEeff is
also affected by the Tf, i.e. the image contrast will vary
slightly with Tf. However, tumours were always easily visua-
lized and, altogether, the range of Tfs used in the study
might only affect the results to a minor extent.
The most time consuming process in the volume de-
termination was probably when adjusting the threshold
value in images where the global segmentation had
failed. To reduce the time of analysis one could e.g. cal-
culate an average volume based on two extreme segmen-
tations; one including most of the border, and one
excluding it. Such a procedure would, however, overesti-
mate the volume, especially for small voxel-to-diameter
ratios, where asymmetry between over- and underestimated
volume errors is more pronounced (Table 3). In situations
when small tumours require polygon delineation of the
tumour border, the decision to assign voxels intersected by
the polygon line to the tumour or the background compart-
ment, will require asymmetry consideration since it might
have a significant effect on the volume estimation (Table 3).
The tumour density assumption (1.0 g/cm3) might be an
underestimation that would account for the fact that the
relations between the determined masses (m3D-160, m2D
and mGB) and the weight (mT) were less than unity. An-
other contributing factor could be the inherent uncertainty
in the digital balance, since errors in the predictor used in
regression analysis are typically manifested as a decrease of
the slope coefficient towards zero [24]. These two consid-
erations are justified by the fact that the slope was 1.01
when m3D-160 and m2D were compared directly to each
other, thus excluding the density effect and predictor
uncertainties.
Table 3 Influence of partial volume effect on volume
determination. The maximum possible influence of the
partial volume effect (PVE) on tumour volume
estimations, assuming isotropic voxels and a spherical
tumour, determined by simulations
Voxels/diameter
(mm−1)
Maximum relative volume difference (%)
overestimated underestimated
70 6 −6
45 10 −10
28 16 −14
12 39 −31
The voxels-per-tumour-diameter ratio is listed with the corresponding results
from the simulation. The relative difference between over- and underestimated
tumour volumes and the analytically calculated volume are given as a percentage
of true tumour volume.
Table 1 The coefficient of variation (CV) calculated for
the five intraobserver variability assessments. The CV is
based on 10 volume calculations performed on each of
the five image series
mT (g) Method CV (%)
0.01 3D-160 3.1
2D 6.9
0.10 3D-160 3.1
0.87 3D-160 2.1
2D 1.9
Table 2 Interobserver variation. The interobserver
variation of tumour mass measurements for three
observers given as relative deviation (in per cent) from
the average value of the mass (n = 10) obtained by
observer 1 for three different tumours and two imaging
methods studied
Mean m (g) Method Interobserver variation (%)
Obs1 Obs2 Obs3
0.02 3D-160 − 0.7 −4.7
0.02 2D − 23 11
0.10 3D-160 − 1.2 −4.3
0.91 3D-160 − −1.4 0.1
0.99 2D − 2.2 −9.0
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Few studies were found in the literature where the ac-
curacy of MRI based tumour size measurement was veri-
fied by e.g. comparison with weight after resection. He
et al. found a correlation of R2 = 0.96 (n = 7) when com-
paring volumes of pancreatic tumours in mice from T2-
weighted 2D MR images (similar to our 2D method),
acquired at 4.7 T, for 0.2–2.0 g tumours [6]. We
obtained a similar correlation (R2 = 0.96, n = 9) but for
smaller tumours (0.01–0.2 g) since we used six times
smaller voxel volume, i.e. the influence of PVE might be
comparable. Other groups have reported MRI tumour
size measurements in mice but without verification with
tumour weight, e.g. [7-9]. One group reported MRI mea-
surements of tumours in mouse pancreas down to
0.14 g at 7.0 T using sequence parameters similar to our
2D method (T2-weighted RARE sequence, 0.015 mm3
voxels), but verified the volume determination by one
phantom measurement only [9].
Using high resolution microCT (7 min acquisition time,
voxel size of 813 μm3, voxel volume of 0.0005 mm3) a close
correlation was found for 0.02–0.25 g s.c. tumours in mice,
verified by weight after resection (R2=0.97, n=20) [12].
Thus, microCT is a fast and accurate method, but the
absorbed dose delivered to the animal, and especially to the
tumour tissue, is a confounding factor in therapy response
assessments.
The generally faster T1-weighted sequences have also
been used for tumour imaging (e.g. [8]). Often however,
the tumour and surrounding tissue have similar T1-values,
thus requiring use of contrast agents. T1-weighted
sequences without contrast agents may be useful for im-
aging tumours in e.g. the bladder wall, where fluid con-
stitutes the surrounding tissue, due to widely different
T1-values in fluid and solid tissue [7].
Conclusion
This study shows the feasibility of accurate and precise
MRI based size measurement of small tumours in mice.
Furthermore, short acquisition times that allow additional
MR investigations within the same session can be realized
by careful selection of MR sequence parameters, e.g. using
2D instead of 3D methods and optimal voxel size.
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